SPHDF Message Board Post 9045172 | Santhera Pharms Hldgs...
home / stock / sphdf / sphdf message board
0piston
(investorshub)
Posted on: Nov/04/2014 12:37:30
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=107816027
$SPHDF is one step ahead in DMD submission!
News, Short Squeeze, Breakout and More Instantly...
Santhera Pharms Hldgs Ltd Company Name:
SPHDF Stock Symbol:
Market:
-
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full R...
-
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted...
-
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera AGAMREE is the first DMD...